Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12747232-B2

Patent

Publication Date

2026-09-29

Expiration Date


Abstract

The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.

Core Innovation

The disclosed subject matter includes heteroaryl-substituted pyrazole-pyrimidine compounds and heterocyclic compounds featuring nitrogen-containing aromatic cores, along with associated pharmaceutically acceptable salts, stereoisomers, deuterated analogs, prodrugs, and tautomers. These compounds act as LRRK2 inhibitors, with tested examples demonstrating inhibition of LRRK2 G2019S at IC50 values below 30 nM. The independent claim covers a compound having a depicted structure, or a pharmaceutically acceptable salt, stereoisomer, or mixture of stereoisomers thereof.

The disclosure also encompasses pharmaceutical compositions and methods for the treatment of LRRK2-mediated disorders, including neurodegenerative, inflammatory, and cancer indications. Certain embodiments demonstrate brain penetrance with MDR1-MDCK efflux ratios at or below about five, with 1,2,3-triazole substituents providing improved brain penetration. Furthermore, compounds with a C5-pyrazole attachment show improved metabolic stability compared to a C4 attachment without significant potency loss.

Claims Coverage

The claims identify two inventive features across one independent claim and related dependent claims.

Compound having a depicted structure

The independent claim covers a compound having the depicted structure, or a pharmaceutically acceptable salt, stereoisomer, or mixture of stereoisomers thereof. A dependent claim further specifies a particular depicted compound structure or a pharmaceutically acceptable salt thereof.

Pharmaceutical composition with an excipient

A dependent claim covers a pharmaceutical composition comprising the compound of the independent claim or specified forms thereof, together with a pharmaceutically acceptable excipient.

The claims cover the depicted compound and its pharmaceutically acceptable salt, stereoisomer, or mixture of stereoisomers, as well as a pharmaceutical composition comprising the compound and a pharmaceutically acceptable excipient.

Stated Advantages

Compounds with a C5-pyrazole attachment show improved metabolic stability compared with compounds with a C4 attachment, without significant potency loss.

Compounds with 1,2,3-triazole substituents show improved brain penetration compared with compounds with 1,2,4-triazoles.

Documented Applications

Treatment of LRRK2-mediated diseases and disorders, including neurodegenerative, inflammatory, and cancer indications.

Pharmaceutical compositions comprising the compound, or specified forms thereof, and a pharmaceutically acceptable excipient.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.